GlassScriptPhysician profile
Patricia Rainaldi
NPI 1083902902
$4,787.64
in general payments reported to CMS, 2019-2025
24 companies · $1,227 in 2025
The $1,227 reported for 2025 was more than what 88% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $365 · 2022: $791 · 2023: $1,189 · 2024: $1,216 · 2025: $1,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,577 · Education: $54.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,577.28 |
| Education | $54.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,102.44 | 2021-2025 | Wegovy |
| Abbvie INC. | $489.47 | 2022-2025 | |
| Axsome Therapeutics, INC. | $407.19 | 2024-2025 | Auvelity |
| Lilly USA, LLC | $250.00 | 2023-2025 | Mounjaro, Zepbound |
| Genzyme Corporation | $250.00 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $184.42 | 2024-2025 | Fasenra |
| Medtronic, INC. | $149.26 | 2023-2025 | Linq II |
| Bayer Healthcare Pharmaceuticals INC. | $137.51 | 2023 | |
| Abbott Laboratories | $135.14 | 2024 | Mitraclip |
| Alk-Abello, INC | $129.17 | 2025 | Odactra |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2023 | Rexulti |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2023 | Dupixent |
| Ani Pharmaceuticals, INC. | $125.00 | 2024 | Purified Cortrophin Gel |
| Amgen INC. | $124.82 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.71 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.44 | 2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $123.28 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $120.65 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $115.38 | 2021 | |
| Impel Pharmaceuticals INC. | $114.17 | 2023 | Trudhesa |
| Coloplast Corp | $105.77 | 2024 | |
| Pfizer INC. | $92.87 | 2023 | |
| Novartis Pharmaceuticals Corporation | $81.65 | 2025 | |
| Sanofi-Aventis U.S. LLC | $52.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Rainaldi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.